Accession Number:

AD1048721

Title:

Novel Epigenetic Reprogramming to Inhibit or Reverse EMT in Lung Cancer

Descriptive Note:

Technical Report,01 Jun 2016,31 May 2017

Corporate Author:

Medical University of South Carolina Charleston United States

Personal Author(s):

Report Date:

2017-09-01

Pagination or Media Count:

32.0

Abstract:

Carcinoma of the lung is the leading cause of cancer deaths in the US. The malignant properties of lung cancer, including invasion, metastasis and drug resistance, are driven inpart by the epithelial- mesenchymal transition EMT, which makes this disease very difficult to treat. We hypothesized that TGF links NRP2-dependent signaling to upregulation of EZH2, an epigenetic modifier, and that EMT results from gene expression changes via a pathway of NRP2, ERK, ZEB1 and EZH2. We proposed to test the validity of this linkage, particularly the connection between NRP2, ZEB1 and EZH2, and to evaluate lung cancer susceptibilities to EZH2 inhibitors in combination with other epigenetic modifiers.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE